• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成功应用司库奇尤单抗治疗不同类型银屑病。

Successful Use of Secukinumab in Various Scenarios of Psoriasis.

机构信息

Department of Dermatology & STD, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.

Department of Dermatology & STD, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India;

出版信息

Skinmed. 2020 Oct 1;18(5):274-276. eCollection 2020.

PMID:33160436
Abstract

Psoriasis is a chronic, immune-mediated, genetically determined inflammatory disease, which afflicts the skin and joints. There is a dearth of literature on situations where psoriasis is complicated by significant disability and associated comorbidities. In such situations, conventional treatments are fraught with challenges, which in turn limit their efficacy. We highlight the successful use of secukinumab in unusual and complicated scenarios of psoriasis.

摘要

银屑病是一种慢性、免疫介导、遗传决定的炎症性疾病,影响皮肤和关节。在银屑病导致严重残疾和相关合并症的情况下,文献资料匮乏。在这种情况下,传统治疗方法充满挑战,进而限制了其疗效。我们重点介绍了司库奇尤单抗在银屑病罕见和复杂情况下的成功应用。

相似文献

1
Successful Use of Secukinumab in Various Scenarios of Psoriasis.成功应用司库奇尤单抗治疗不同类型银屑病。
Skinmed. 2020 Oct 1;18(5):274-276. eCollection 2020.
2
Clinical outcomes in patients on secukinumab (Cosentyx ) within a specialist psoriasis clinic: a single centre, retrospective cohort study.在一家专科银屑病诊所中使用司库奇尤单抗(可善挺)治疗的患者的临床结局:一项单中心回顾性队列研究。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e89-e91. doi: 10.1111/jdv.15245. Epub 2018 Oct 1.
3
The successful treatment with ixekizumab in a multi-failure psoriasis patient.司库奇尤单抗成功治疗一名多系统功能衰竭的银屑病患者。
Dermatol Online J. 2018 Sep 10;24(9):13030/qt2qn1p4bz.
4
Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.银屑病治疗的新型治疗方法与靶点
Curr Pharm Biotechnol. 2021;22(1):7-31. doi: 10.2174/1389201021666200629150231.
5
Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece.司库奇尤单抗治疗斑块状银屑病患者的生存率和长期疗效:来自希腊一家三级医院的真实数据。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e82-e84. doi: 10.1111/jdv.15231. Epub 2018 Sep 25.
6
Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.司库奇尤单抗治疗失败的慢性红皮病型银屑病病史患者使用依奇珠单抗的临床经验:病例系列
Br J Dermatol. 2019 Nov;181(5):1106-1107. doi: 10.1111/bjd.18174. Epub 2019 Aug 20.
7
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.司库奇尤单抗在治疗中度至重度银屑病患者中,通过两年治疗展现出持续清除皮肤症状及改善患者报告结局的疗效:CLEAR研究结果
J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6.
8
Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.司库奇尤单抗继发治疗失败的银屑病患者对依奇珠单抗的反应。
Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):119-121. doi: 10.4103/ijdvl.IJDVL_671_19.
9
Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.司库奇尤单抗耐药或反应不完全患者中依奇珠单抗的疗效。
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):e338-e341. doi: 10.1111/jdv.15630. Epub 2019 Apr 29.
10
Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.银屑病患者长期使用司库奇尤单抗的延续性:与患者特征和初始银屑病清除的关联。
Clin Exp Dermatol. 2019 Oct;44(7):e230-e234. doi: 10.1111/ced.13999. Epub 2019 May 22.